Evogene (EVGN) Cash & Equivalents (2016 - 2025)

Evogene (EVGN) has disclosed Cash & Equivalents for 10 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 15.33% to $13.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2025, down 15.33% year-over-year, with the annual reading at $13.0 million for FY2025, 15.33% down from the prior year.
  • Cash & Equivalents hit $13.0 million in Q4 2025 for Evogene, down from $15.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $32.3 million in Q4 2021 to a low of $13.0 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $22.1 million across 5 years, with a median of $20.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 30.08% in 2021 and later dropped 10.35% in 2022.
  • Year by year, Cash & Equivalents stood at $32.3 million in 2021, then fell by 10.35% to $29.0 million in 2022, then decreased by 28.32% to $20.8 million in 2023, then fell by 26.34% to $15.3 million in 2024, then decreased by 15.33% to $13.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for EVGN at $13.0 million in Q4 2025, $15.3 million in Q4 2024, and $20.8 million in Q4 2023.